Skip to main content
AVECHO BIOTECHNOLOGY LIMITED logo

AVECHO BIOTECHNOLOGY LIMITED — Investor Relations & Filings

Ticker · AVE ISIN · AU0000047441 LEI · 529900FA9G9T82C2LV25 ASX Manufacturing
Open in API
Filings indexed 881 across all filing types
Latest filing 2007-08-28 Regulatory Filings
Country AU Australia
Listing ASX AVE

About AVECHO BIOTECHNOLOGY LIMITED

https://avecho.com.au/

Avecho Biotechnology Limited develops and commercializes human and animal health products using its proprietary drug delivery system, Tocopheryl Phosphate Mixture (TPM®). Derived from Vitamin E, TPM® is designed to enhance the solubility and absorption of active ingredients through the skin and digestive tract. The company focuses on applying this technology to pharmaceuticals, nutraceuticals, and animal health sectors. A primary area of development includes medicinal cannabis, where Avecho has produced high-bioavailability cannabidiol (CBD) softgel capsules for therapeutic use. The company’s portfolio also includes applications in pain management and dermatology, leveraging TPM® to improve the delivery of poorly soluble molecules and enhance the efficacy of existing treatments.

Recent filings

Filing Released Lang Actions
Half Yearly Report and Accounts 26 pages ?Kb
Regulatory Filings
2007-08-28 English
Appendix 3B - Exercise of 1,725 Options 8 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) new issue announcement form. It details the allotment of new shares following the exercise of options, including the number of shares issued, the class of securities, and the application for quotation of these shares on the ASX. The document includes specific regulatory references to ASX rules and the Corporations Act, and it is clearly an announcement of a capital change event (exercise of options leading to new shares issued and quoted). There are no financial statements, management discussion, or earnings data present. The document is not a full financial report but a regulatory announcement related to share capital changes. Therefore, the appropriate classification is "Share Issue/Capital Change" (SHA). The document length (11,588 characters) supports that it is a detailed announcement rather than a brief notice or a simple report publication announcement.
2007-08-20 English
Phase 1b Transdermal Insulin Clinical Trial Results 7 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement dated 08 August 2007 from Phosphagenics Limited regarding the positive results of a Phase 1b clinical trial for a transdermal insulin product. It includes detailed clinical trial results, study outlines, and discussion of the outcomes. The document is addressed to the ASX Company Announcements Office and is clearly intended for market release. It is not a full financial report, audit, or regulatory filing but rather a clinical trial results announcement. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a detailed announcement of clinical trial results relevant to investors and the market. This type of document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement to the market that does not fit into other specific financial or governance categories. The document length (15,000 characters) and content confirm it is not a brief report publication announcement or a certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2007-08-07 English
Appendix 3B 8 pages ?Kb
Regulatory Filings
2007-08-01 English
Phosphagenics lists on International OTCQX Market in the US 3 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 10 July 2007 regarding Phosphagenics Limited listing its Level 1 American Depository Receipts (ADR) on the International OTCQX Market in the U.S. It describes the listing event, the market tier, and the company's business focus. There are no financial statements, detailed financial data, or management discussion of results. The document is a market announcement about a capital market listing event rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best as a Capital/Financing Update (CAP) because it relates to the company's capital market activity and listing status update.
2007-07-09 English
Nestle Nutrition - clincial program to progress as planned 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement dated 09 July 2007 from Phosphagenics Limited regarding the extension of an option agreement with Nestlé Nutrition. It discusses the progress of a clinical program and commercial negotiations but does not contain any financial statements, detailed financial performance data, or regulatory filings. The content is primarily a market announcement about a business development and partnership extension. It is not a report, transcript, or detailed financial disclosure. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for general regulatory announcements and market updates that do not fit other specific categories.
2007-07-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.